

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5906331

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CUREVAC AG	11/19/2019
RECEIVING PARTY DATA	
Name:	CUREVAC REAL ESTATE GMBH
Street Address:	PAUL-EHRLICH-STR. 15
City:	TÜBINGEN
State/Country:	GERMANY
Postal Code:	72076
PROPERTY NUMBERS Total: 11	
Property Type	Number
Patent Number:	8383340
Application Number:	15195901
Application Number:	15317579
Application Number:	15566010
Application Number:	15566980
Application Number:	15044094
Application Number:	16005131
Application Number:	15738641
Application Number:	15580092
Application Number:	15750745
Application Number:	16077973
CORRESPONDENCE DATA	
Fax Number:	(512)334-2999
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5123342900
Email:	jnorman@phiplaw.com
Correspondent Name:	PARKER HIGHLANDER PLLC
Address Line 1:	1120 S. CAPITAL OF TEXAS HWY.
Address Line 2:	BUILDING ONE, SUITE 200
Address Line 4:	AUSTIN, TEXAS 78746

PATENT

ATTORNEY DOCKET NUMBER:	CRVC.P0001
NAME OF SUBMITTER:	JENNIFER NORMAN-WOLFE
SIGNATURE:	/Jennifer Norman-Wolfe/
DATE SIGNED:	01/11/2020
Total Attachments: 5 source=AssignmentCureVacRealEstate#page1.tif source=AssignmentCureVacRealEstate#page2.tif source=AssignmentCureVacRealEstate#page3.tif source=AssignmentCureVacRealEstate#page4.tif source=AssignmentCureVacRealEstate#page5.tif	

CRVC.P0049US, CRVC.P0153US, CRVC.P0165US,
CRVC.P0172US, CRVC.P0173US, CRVC.P0176US,
CRVC.P0176US.C1, CRVC.P0183US, CRVC.P0185US
CRVC.P0193US, CRVC.P0208US, CRVC.P0250US

ASSIGNMENT

This Patent Assignment ("Assignment") is made and entered into by and between **CureVac AG**, a company organized and existing under the laws Germany, having a place of business at Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany (the "Assignor") and **CureVac Real Estate GmbH**, a company organized and existing under the laws of Germany, having a place of business at Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany (the "Assignee").

WHEREAS, Assignor has agreed to assign and transfer to Assignee, and Assignee has agreed to acquire and accept from Assignor, Assignor's rights in the following patent applications (the "Assigned Patents"):

U.S. Application No. 12/520,172, entitled "METHOD FOR PURIFYING RNA ON A PREPARATIVE SCALE BY MEANS OF HPLC," filed October 20, 2009, now U.S. Patent No. 8,383,340, which is a U.S. nationalization of International Application No. PCT/EP2007/011294, which claims priority to German Application No. 10 2006 061 015.6 (CRVC.P0049US; CU01P049WOUS);

U.S. Reissue Application No. 16/442,939, entitled "METHOD FOR PURIFYING RNA ON A PREPARATIVE SCALE BY MEANS OF HPLC," filed June 17, 2019, which is reissue of U.S. Application No. 12/520,172 (CRVC.P0049RE)

U.S. Application No. 15/195,901, entitled "METHODS FOR RNA ANALYSIS," filed June 28, 2016, which is a U.S. nationalization of International Application No. PCT/EP2014/003482, which claims priority to International Application No. PCT/EP2013/003947 (CRVC.P0153US; CU01P153WO1US);

U.S. Application No. 15/317,579, entitled "METHODS AND MEANS FOR ENHANCING RNA PRODUCTION," filed December 9, 2016, which is a U.S. nationalization of International Application No. PCT/EP2015/001164, which claims priority to International Application No. PCT/EP2014/001577 (CRVC.P0165US; CU01P165WO2US);

U.S. Application No. 15/566,010, entitled "METHOD FOR PRODUCING RNA COMPOSITIONS," filed October 12, 2017, which is a U.S. nationalization of International Application No. PCT/EP2016/000607, which claims priority to International Application No. PCT/EP2015/000771 (CRVC.P0172US; CU01P172WO1US);

U.S. Application No. 15/566,980, entitled "LYOPHILIZATION OF RNA," filed October 16, 2017, which is a U.S. nationalization of International Application No. PCT/EP2016/000622, which claims priority to International Application No. PCT/EP2015/000818 (CRVC.P0173US; CU01P173WO1US);

U.S. Application No. 15/044,094, entitled "METHOD FOR PRODUCING RNA," filed February 15, 2016, now U.S. Patent No. 10,017,826, which is a continuation of International Application No. PCT/EP2015/000959 (CRVC.P0176US; CU01P176US);

U.S. Application No. 16/005,131, entitled "METHOD FOR PRODUCING RNA," filed June 11, 2018, which is continuation of U.S. Application No. 15/044,094, which is a continuation of International Application No. PCT/EP2015/000959 (CRVC.P0176US.C1; CU01P176USC1);

U.S. Application No. 15/738,641, entitled "METHOD FOR ANALYSIS OF AN RNA MOLECULE," filed December 21, 2017, which is a U.S. nationalization of International Application No. PCT/EP2016/001121, which claims priority to International Application No. PCT/EP2015/001336 (CRVC.P0183US; CU01P183WO1US);

U.S. Application No. 15/580,092, entitled "A METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION," filed December 6, 2017, which is a U.S. nationalization of International Application No. PCT/EP2016/062152, which claims priority to International Application No. PCT/EP2015/062002 (CRVC.P0185US; Maiwald Ref. C09807WO2US);

U.S. Application No. 15/750,745, entitled "METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE," filed February 6, 2018, which is a U.S. nationalization of International Application No. PCT/EP2016/068702, which claims priority to International Application No. PCT/EP2015/068398 (CRVC.P0193US; Maiwald Ref.: C09828WO2US);

U.S. Application No. 16/077,973, entitled "METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION," filed August 14, 2018, which is a U.S. nationalization of International Application No. PCT/EP2016/053194 (CRVC.P0208US; Maiwald Ref.: C09927WOUS);

International Application No. PCT/EP2018/062998, entitled "METHOD FOR DETERMINING AT LEAST ONE QUALITY PARAMETER OF AN RNA SAMPLE," filed May 17, 2018, which claims priority to International Application No. PCT/EP2017/061859 (CRVC.P0250).

NOW, THEREFORE, in consideration of the premises, mutual covenants and provisions herein contained, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree to execute this Assignment, as follows:

1.0 Assignment. Assignor has assigned and/or by these presents does hereby assign, transfer and convey unto Assignee, Assignor's whole and entire right, title and interest for the United States and for all other countries throughout the world (i) in and to the inventions claimed or disclosed in the Assigned Patents, including all patents granting from said applications on said Assigned

Patents or any continuation, continuation-in-part, division, renewal, substitute, reexamination or reissue thereof, including any patents in the United States and in all other countries throughout the world obtained based upon a claim of priority to any patent or patent application on said Assigned Patents as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law, as well as the right to claim priority to any patent or patent application on said Assigned Patents as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law, and (ii) in and to all rights to sue for and collect damages resulting from past, present and future infringement of said patents and patent applications in (i).

2.0 Enjoyment. The patents and patent applications subject to Paragraph 1 shall be held and enjoyed by Assignee, for Assignee's use and benefit, and for Assignee's legal representatives and assigns, to the full end of the term or terms for which same may be granted, as fully and entirely as the same would have been held by Assignor had this assignment and transfer not been made.

3.0 Authorize and Request. Assignor authorizes and requests the issuing authority to issue any and all United States and foreign patents granted on such patents and patent applications in 1.0(i) to the Assignee.

4.0 Warrant And Covenant. Assignor warrants and covenants that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the Assignor, and that the full right to convey the same as herein expressed is possessed by the Assignor.

5.0 Assistance. The parties to this Assignment shall use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things, necessary or advisable to consummate the transactions contemplated by this Assignment. Without limiting the foregoing, each of Assignor and Assignee shall cooperate with the other without any further consideration to execute and deliver, or use commercially reasonable efforts to cause to be executed and delivered, all documents as may reasonably be necessary to secure the vesting in Assignee of all rights assigned to Assignee by this Assignment, including without limitation any documents required to record this Assignment with local patent offices, and all rightful oaths, declarations, and other papers.

6.0 Binding. The Assignment is binding on the heirs, assigns, representatives and successors of the Assignor and extends to the successors, assigns and nominees of the Assignee.


7.0 Effectiveness. The assignment of said inventions is effective as of the date of execution of the Assignor indicated below.

(Signature page follows)


CRVC.P0049US, CRVC.P0153US, CRVC.P0165US,
CRVC.P0172US, CRVC.P0173US, CRVC.P0176US,
CRVC.P0176US.C1, CRVC.P0183US, CRVC.P0185US
CRVC.P0193US, CRVC.P0208US, CRVC.P0250US

IN WITNESS WHEREOF, Assignor has executed this Patent Assignment, or has caused this Patent Assignment to be executed on its behalf by a representative duly authorized, all as of the date set forth below.

CureVac AG


By: 
Name: Franz-Werner Haas
Title: Chief Operating Officer
Date: 11.11.2019

BEFORE ME, the undersigned authority, on this 19 day of November, 2019 personally appeared Franz-Werner Haas, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.



Witness Sandra Gougel

IN WITNESS WHEREOF, Assignor has executed this Patent Assignment, or has caused this Patent Assignment to be executed on its behalf by a representative duly authorized, all as of the date set forth below.

CureVac AG

By: 
Name: Mariola Fotin-Mieczek
Title: Chief Technology Officer
Date: 11.11.2019

BEFORE ME, the undersigned authority, on this 19 day of November, 2019 personally appeared Mariola Fotin-Mieczek, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.


Witness Sandra Gougel

IN WITNESS WHEREOF, Assignee has executed this Patent Assignment, or has caused this Patent Assignment to be executed on its behalf by a representative duly authorized, all as of the date set forth below.

CureVac Real Estate GmbH

By: [Signature]
Name: Florian von der Mübe Dr. Florian von der Mübe
Title: ~~Chief Production Officer~~ Geschäftsleitung
Date: 13.11.19

BEFORE ME, the undersigned authority, on this 13 day of November, 2019 personally appeared Florian von der Mübe, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.

[Signature]
Witness: Jasmin Schlienz

IN WITNESS WHEREOF, Assignee has executed this Patent Assignment, or has caused this Patent Assignment to be executed on its behalf by a representative duly authorized, all as of the date set forth below.

CureVac Real Estate GmbH

By: [Signature]
Name: Dr. Simone Dohmann
Title: OR SIMONE DOHMANN
Date: GF
21.11.19

BEFORE ME, the undersigned authority, on this 21 day of November, 2019 personally appeared Simone Dohmann, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.

[Signature]
Witness: Leonie Stark